TracheobronchomalaciaNCT04169282
PEEP Mask for Tracheobronchomalacia-Induced Cough
A study testing nPEP (non-invasive positive expiratory pressure) mask in people with Tracheobronchomalacia, run by Duke University at 1 site in United States.
Trial summary
This study aims to determine if an expiratory resistance device that delivers non-invasive positive expiratory pressure (nPEP) will reduce or stop coughing, reduce airway resistance and improve quality of life in patients with tracheobronchomalacia (TBM) who are not candidates for tracheal stenting. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Tracheobronchomalacia
- What is being tested?
- nPEP (non-invasive positive expiratory pressure) mask
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteUnited States
- Study dates
- 30 Aug 2021to 15 Aug 2022
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥18 years
- Visualization of ≥50% collapse of the trachea or mainstem bronchus on CT scan or bronchoscopy
- No upper or lower respiratory infection within 4 weeks
- Having capacity to provide legal written informed consent
Who cannot join
- History of tracheobronchoplasty or chronic tracheal stenting
- Current tracheostomy
- History of external chest trauma
- History of:
- Active treatment for Lung cancer
- Lung transplantation
Show all 10Show fewer
- Unstable congestive heart failure
- History of spontaneous pneumothorax
- Other medical conditions that interfere with participation in the study
- Pregnant women
Trial locations and contacts
1 site in 1 country.
United States1 site
Duke University Health System
Durham, North Carolina, 27710
About this study
Official title: Non-invasive Positive Expiratory Pressure Mask (PEEP-Mask) for Tracheobronchomalacia Associated Cough
This study aims to determine if an expiratory resistance device that delivers non-invasive positive expiratory pressure (nPEP) will reduce or stop coughing, reduce airway resistance and improve quality of life in patients with tracheobronchomalacia (TBM) who are not candidates for tracheal stenting.
Read the detailed description
PROSPECTIVE:
Twenty subjects with chronic cough and TBM diagnosed by bronchoscopy or computed tomography (CT) scan will be recruited to enroll 12 participants. Comorbid conditions that can cause chronic cough, such as asthma, COPD, and GERD, must be treated if present, for subjects to qualify. At the pre-baseline visit (V0), after obtaining verbal informed consent, each subject will complete validated cough questionnaires to quantify their cough severity and cough-related QOL at baseline. The baseline visit (V1) will occur in-person approximately two weeks later, after a run-in period to minimize observation bias related to the cough questionnaires. Written consent will be performed at this visit. At V1, the cough questionnaires will be repeated and subjects' airway resistance and reactance will be measured with impulse oscillometry (IOS). A study physician will perform a physical exam and determine eligibility. Eligible subjects will then be given the nPEP device by the study team and instructed on its use. Approximately four to six weeks after device delivery, at the follow-up visit (V3), cough questionnaires and IOS will be repeated and they will be asked for feedback regarding device design and user experience. Subjects may then be entered into a cohort for up to six additional months, during which there will be no study visits or procedures, but subjects may be contacted by investigators for additional narrative feedback on the device and its use.
Study subjects will be given an nPEP device to use for four to six weeks. During this time participants will be asked to remain on their current medical regimen and not to make any dose changes or add new drugs, unless indicated by their primary care provider. Impulse oscillometry will be measured at V1 and 4-6 weeks later at V3 to assess effect of the nPEP device on airway physiology. A lung CT scan will be performed at V2.
RETROSPECTIVE:
This device was tried on two individuals and it was initiative and was beneficial. Many patients are not candidates for tracheobronchoplasty itself due to medical comorbidities, prefer to avoid the associated risks, or are not candidates for the required tracheal stenting due to trachea size or anatomy. These patients are left without a viable therapeutic option for their severe cough.
Continuous positive airway pressure (CPAP) devices have been reported to stop or prevent cough in TBM, presumably through pneumatic stenting the large airways to maintain their patency during exhalation. CPAP devices, however, are not labeled for this indication and their functional utility is very limited given size of the device, need for a power source, and multiple steps to don the equipment that are not easily completed while actively and uncontrollably coughing.
The physicians aimed to provide positive airway pressure at a low cost and through readily accessible means, in order to abort coughing paroxysms in patients who were not candidates for tracheal stenting and did not have access to commercial CPAP devices. Patients at Duke University Hospital referred to the Interventional Pulmonary service for evaluation of severe, debilitating TBM-related cough and possible tracheal stenting, but who were not candidates for tracheal stenting given their airway anatomy, were given positive end expiratory pressure (PEEP) masks assembled using existing hospital supplies. Specifically, a standard, adjustable (5-20 cm H2O) positive end expiratory pressure (PEEP) valve manufactured for attachment to a manual resuscitation (commonly known as bag-valve-mask) device was attached directly to a flexible face mask, also from a manual resuscitation device. Patients were instructed by their physicians how to use the PEEP masks. The patients used the PEEP mask immediately during their clinical encounter and were given a mask to take home. (The device was created by fellow, Lindsay Boole.)
This was a limited intervention for a very small number of patients (two), specifically identified as being referred to Duke Interventional Pulmonary service with severe cough related to TBM, but with anatomy that ruled them out as candidates for tracheal stenting. There were no formal data collected and no separate follow-up for the purpose of this project (though patients had ongoing clinical follow-up per standard of care). The patients' subjective improvement with the masks was submitted as a case report abstract and poster at the American College of Chest Physician meeting in 2017.
Other physicians asked Dr. Boole about the mask and if it could be used for their patients. Therefore, the investigators would like to request a retrospective review of all patients that used the PEEP mask between January 1, 2009 and August 20, 2019 to be included in this pilot study. Approximately 15 records will be reviewed.
- Conditions
- Tracheobronchomalacia
- Being tested
- nPEP (non-invasive positive expiratory pressure) mask
- Keywords
- tracheobronchomalacia, TBM, cough
- Medical subject headings
- Tracheobronchomalacia, Cough
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
nPEP (non-invasive positive expiratory pressure) maskDevice
Positive end expiratory pressure (PEEP) mask
| Study group | Role | What they receive |
|---|---|---|
| nPEP Recipients | Experimental | Single-patient, adjustable expiratory resistance device that provides positive pressure (5 to 20 cm H2O) during expiration Receives: Device: nPEP (non-invasive positive expiratory pressure) mask |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Cough Severity as Measured by the Cough Visual Analog Scale (VAS)
The primary objective is to determine if use of the nPEP device will change cough severity. Responses to the Cough VAS range from 0-100 mm, with higher scores corresponding to worse outcomes.
Measured: Baseline, two weeks
Change in Quality of Life as Measured by the Cough-Specific Quality-of-Life Questionnaire (CQLQ)
The CQLQ score ranges from 28 to 112, with higher scores corresponding to worse outcomes.
Measured: Baseline, two weeks
Change in Quality of Life as Measured by the Leicester Cough Questionnaire (LCQ)
The LCQ score ranges from 19 to 133, with lower scores corresponding to worse outcomes.
Measured: Baseline, two weeks
Secondary outcomes (1)
Proximal Airway Reactance at 5 Hz (X5) as Assessed by Impulse Oscillometry
The secondary objective is to determine if use of the nPEP device changes airway physiology, specifically proximal airway reactance, as assessed by impulse oscillometry. Reactance at 5 Hz (X5) relates to the physical properties of the lung parenchyma and its ability to expand and facilitate alveolar filling. A more negative X5 value indicates less elasticity of the lung.
Measured: Baseline, two weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Nov 2019
- Study start30 Aug 2021
- Primary completion15 Aug 2022
- Study completion15 Aug 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for TracheobronchomalaciaStudies of the same condition, open and under way.
- More trials run by Duke UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Lead sponsor
- Duke University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Loretta G Que, MD, Principal investigator, Duke University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04169282
- Sponsor's protocol ID
- Pro00102498
- Status last verified
- Sep 2023
- First submitted
- 14 Nov 2019
- Last updated
- 28 Sep 2023
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Sep 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Non-invasive Positive Expiratory Pressure Mask (PEEP-Mask) for Tracheobronchomalacia Associated Cough
- ClinicalTrials.gov ID
- NCT04169282
- Acronym / sponsor ID
- Pro00102498
- Conditions
- Tracheobronchomalacia
- Keywords
- tracheobronchomalacia, TBM, cough
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 10 participants (actual)
- Lead sponsor
- Duke UniversityUniversity, hospital or other
- Study start
- 30 Aug 2021 (actual)
- Primary completion
- 15 Aug 2022 (actual)
- Study completion
- 15 Aug 2022 (actual)
- First posted
- 19 Nov 2019 (actual)
- Results
- Posted 28 Sep 2023
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to determine if an expiratory resistance device that delivers non-invasive positive expiratory pressure (nPEP) will reduce or stop coughing, reduce airway resistance and improve quality of life in patients with tracheobronchomalacia (TBM) who are not candidates for tracheal stenting.
Detailed description
PROSPECTIVE:
Twenty subjects with chronic cough and TBM diagnosed by bronchoscopy or computed tomography (CT) scan will be recruited to enroll 12 participants. Comorbid conditions that can cause chronic cough, such as asthma, COPD, and GERD, must be treated if present, for subjects to qualify. At the pre-baseline visit (V0), after obtaining verbal informed consent, each subject will complete validated cough questionnaires to quantify their cough severity and cough-related QOL at baseline. The baseline visit (V1) will occur in-person approximately two weeks later, after a run-in period to minimize observation bias related to the cough questionnaires. Written consent will be performed at this visit. At V1, the cough questionnaires will be repeated and subjects' airway resistance and reactance will be measured with impulse oscillometry (IOS). A study physician will perform a physical exam and determine eligibility. Eligible subjects will then be given the nPEP device by the study team and instructed on its use. Approximately four to six weeks after device delivery, at the follow-up visit (V3), cough questionnaires and IOS will be repeated and they will be asked for feedback regarding device design and user experience. Subjects may then be entered into a cohort for up to six additional months, during which there will be no study visits or procedures, but subjects may be contacted by investigators for additional narrative feedback on the device and its use.
Study subjects will be given an nPEP device to use for four to six weeks. During this time participants will be asked to remain on their current medical regimen and not to make any dose changes or add new drugs, unless indicated by their primary care provider. Impulse oscillometry will be measured at V1 and 4-6 weeks later at V3 to assess effect of the nPEP device on airway physiology. A lung CT scan will be performed at V2.
RETROSPECTIVE:
This device was tried on two individuals and it was initiative and was beneficial. Many patients are not candidates for tracheobronchoplasty itself due to medical comorbidities, prefer to avoid the associated risks, or are not candidates for the required tracheal stenting due to trachea size or anatomy. These patients are left without a viable therapeutic option for their severe cough.
Continuous positive airway pressure (CPAP) devices have been reported to stop or prevent cough in TBM, presumably through pneumatic stenting the large airways to maintain their patency during exhalation. CPAP devices, however, are not labeled for this indication and their functional utility is very limited given size of the device, need for a power source, and multiple steps to don the equipment that are not easily completed while actively and uncontrollably coughing.
The physicians aimed to provide positive airway pressure at a low cost and through readily accessible means, in order to abort coughing paroxysms in patients who were not candidates for tracheal stenting and did not have access to commercial CPAP devices. Patients at Duke University Hospital referred to the Interventional Pulmonary service for evaluation of severe, debilitating TBM-related cough and possible tracheal stenting, but who were not candidates for tracheal stenting given their airway anatomy, were given positive end expiratory pressure (PEEP) masks assembled using existing hospital supplies. Specifically, a standard, adjustable (5-20 cm H2O) positive end expiratory pressure (PEEP) valve manufactured for attachment to a manual resuscitation (commonly known as bag-valve-mask) device was attached directly to a flexible face mask, also from a manual resuscitation device. Patients were instructed by their physicians how to use the PEEP masks. The patients used the PEEP mask immediately during their clinical encounter and were given a mask to take home. (The device was created by fellow, Lindsay Boole.)
This was a limited intervention for a very small number of patients (two), specifically identified as being referred to Duke Interventional Pulmonary service with severe cough related to TBM, but with anatomy that ruled them out as candidates for tracheal stenting. There were no formal data collected and no separate follow-up for the purpose of this project (though patients had ongoing clinical follow-up per standard of care). The patients' subjective improvement with the masks was submitted as a case report abstract and poster at the American College of Chest Physician meeting in 2017.
Other physicians asked Dr. Boole about the mask and if it could be used for their patients. Therefore, the investigators would like to request a retrospective review of all patients that used the PEEP mask between January 1, 2009 and August 20, 2019 to be included in this pilot study. Approximately 15 records will be reviewed.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| nPEP Recipients | Experimental | Device: nPEP (non-invasive positive expiratory pressure) maskSingle-patient, adjustable expiratory resistance device that provides positive pressure (5 to 20 cm H2O) during expiration |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age ≥18 years
- Visualization of ≥50% collapse of the trachea or mainstem bronchus on CT scan or bronchoscopy
- No upper or lower respiratory infection within 4 weeks
- Having capacity to provide legal written informed consent
Key exclusion criteria (10 listed)
- History of tracheobronchoplasty or chronic tracheal stenting
- Current tracheostomy
- History of external chest trauma
- History of:
- Other medical conditions that interfere with participation in the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| nPEP (non-invasive positive expiratory pressure) maskPositive end expiratory pressure (PEEP) mask | Device | nPEP Recipients |
Primary outcome
Change in Cough Severity as Measured by the Cough Visual Analog Scale (VAS)
Time frame: Baseline, two weeks
The primary objective is to determine if use of the nPEP device will change cough severity. Responses to the Cough VAS range from 0-100 mm, with higher scores corresponding to worse outcomes.
Change in Quality of Life as Measured by the Cough-Specific Quality-of-Life Questionnaire (CQLQ)
Time frame: Baseline, two weeks
The CQLQ score ranges from 28 to 112, with higher scores corresponding to worse outcomes.
Change in Quality of Life as Measured by the Leicester Cough Questionnaire (LCQ)
Time frame: Baseline, two weeks
The LCQ score ranges from 19 to 133, with lower scores corresponding to worse outcomes.
1 secondary outcome
Proximal Airway Reactance at 5 Hz (X5) as Assessed by Impulse Oscillometry
Time frame: Baseline, two weeks
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Sep 2023.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Tracheobronchomalacia
Not yet recruitingObservational study
Laryngotracheal Lesions in Adults With Long-Term Tracheostomy
Laryngotracheal Lesions, Tracheostomy Complications
Enrolling by invitation
Feasibility of Tracheobronchial Reconstruction Using Allogenic Aortic Patch in Children
Trachea Diseases, Tracheal Stenosis
Recruiting
Effect of CPAP on 6-Minute Walk Test Outcomes in Patients With ECAC
Tracheobronchomalacia, Excessive Dynamic Airway Collapse
Recruiting
Bioresorbable Airway Splint Pivotal Clinical Trial
Tracheobronchomalacia
Enrolling by invitation
Primary Posterior Tracheopexy Prevents Tracheal Collapse
Oesophageal Atresia With Tracheo-Oesophageal Fistula, Tracheomalacia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Loretta G Que, MD principal investigator
Duke University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing nPEP (non-invasive positive expiratory pressure) mask in people with Tracheobronchomalacia, run by Duke University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 28 Sep 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Cough Severity as Measured by the Cough Visual Analog Scale (VAS) (time frame: Baseline, two weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2023.